%0 Journal Article
%A Kostareli, Efterpi
%A Hielscher, Thomas
%A Zucknick, Manuela
%A Baboci, Lorena
%A Wichmann, Gunnar
%A Holzinger, Dana
%A Mücke, Oliver
%A Pawlita, Michael
%A Del Mistro, Annarosa
%A Boscolo-Rizzo, Paolo
%A Da Mosto, Maria Cristina
%A Tirelli, Giancarlo
%A Plinkert, Peter
%A Dietz, Andreas
%A Plass, Christoph
%A Weichenhan, Dieter
%A Hess, Jochen
%T Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients.
%J Epigenetics
%V 11
%N 1
%@ 1559-2308
%C Austin, Tex.
%I Landes Bioscience
%M DKFZ-2017-04963
%P 61 - 73
%D 2016
%X Infection with high-risk types of human papilloma virus (HPV) is currently the best-established prognostic marker for head and neck squamous cell carcinoma (HNSCC), one of the most common and lethal human malignancies worldwide. Clinical trials have been launched to address the concept of treatment de-escalation for HPV-positive HNSCC with the final aim to reduce treatment related toxicity and debilitating long-term impacts on the quality of life. However, HPV-related tumors are mainly restricted to oropharyngeal SCC (OPSCC) and there is an urgent need to establish reliable biomarkers for all patients at high risk for treatment failure. A patient cohort (n = 295) with mainly non-OPSCC (72.9
%K Biomarkers, Tumor (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:26786582
%2 pmc:PMC4846111
%R 10.1080/15592294.2015.1137414
%U https://inrepo02.dkfz.de/record/128951